Zai Lab Ltd.

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Yap will help advance Zai Lab’s preclinical and clinical pipeline Dr. Yap will help advance Zai Lab’s preclinical and clinical pipeline

Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board

ACADIA Pharma

Arrowhead Pharmaceuticals

China Biologic Products Holdings

Galapagos

Natera

Spark Therapeutics

Many of these biotech companies are beating the Nasdaq Biotech Index. With cutting-edge therapies, these are great names to buy.

7 Exciting Biotech Stocks to Buy Now

BeiGene

BeiGene and Zai Lab offer two ways to invest in what could be a big opportunity.

Buy These 2 Stocks to Access China's Huge Healthcare Market

SHANGHAI, China and SAN FRANCISCO, Oct.  25, 2019  (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that its partner MacroGenics, Inc. (NASDAQ: MGNX) has dosed the first patient in the Phase 2/3 MAHOGANY clinical trial of margetuximab, an investigational, Fc-optimized monoclonal antibody targeting HER2, in combination with a checkpoint inhibitor, with or without chemotherapy, as a potential first-line treatment for patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. 

Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer

SHANGHAI, China, and SAN FRANCISCO, Oct.  24, 2019  (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that its partner GlaxoSmithKline plc (GSK) has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer patients, who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy. Patient selection is based on an FDA-approved companion diagnostic for Zejula.

Zai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer

SHANGHAI, China and SAN FRANCISCO, Oct.  04, 2019  (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder and Chief Executive Officer, will speak at the Forbes Global CEO Conference being held on October 15-16, 2019, in Singapore.

Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference

SHANGHAI, China, and SAN FRANCISCO, Sept.  29, 2019  (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced its partner GlaxoSmithKline plc results from PRIMA (ENGOT-OV26/GOG-3012). PRIMA is a double-blind, randomized, placebo-controlled Phase 3 study of Zejula (niraparib) as a maintenance therapy in women with first-line ovarian cancer following a response to platinum-based chemotherapy. Niraparib treatment resulted in a 38% reduction in the risk of disease progression or death in the overall population (PFS, HR 0.62; 95% CI, 0.50–0.75; p

Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer

Zai Lab Limited (ZLAB) CEO Ying Du on Q2 2019 Results - Earnings Call Transcript

-- Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT--  SHANGHAI, China and SAN FRANCISCO, Sept.  03, 2019  (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or “the Company”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial-stage biopharmaceutical company, today announced financial results for the six months ended June 30, 2019 and provided a corporate update.

Zai Lab Announces Financial Results and Corporate Update for the Six Months Ended June 30, 2019

Study demonstrated comparable profile to non-Chinese patients  Clinical study published in The Oncologist

Zai Lab Announces Publication of Pharmacokinetic Study of Niraparib in Chinese Ovarian Cancer Patients

SHANGHAI, China and SAN FRANCISCO, Aug.  26, 2019  (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or “the Company”) (NASDAQ: ZLAB), a China and US-based innovative commercial-stage biopharmaceutical company, today announced that members of the senior management team will be presenting at the following upcoming conferences this September. Details of the conferences are as follows:

Zai Lab Announces Upcoming Presentations at September Conferences

Incyte

Incyte Corp.  said Tuesday it will receive an upfront payment of $17.5 million as part of a license agreement with Zai Lab Ltd.

Incyte enters license pact with Zai Lab to commercialize its cancer treatment in Greater China

Zai Lab has built one of the most experienced leadership teams in China, which is currently significantly underrated by the market.

News for Zai Lab Ltd. Stock (ZLAB)